Radius Reveals Abaloparatide Delay, After Playing Up Launch Readiness

FDA's review of filing for osteoporosis abaloparatide delayed by three months to June 30, bringing it closer to the action date for Amgen's competing anabolic agent romosuzumab, which has an action date of July 19.